Abstract
It is reported that 7,8-dihydroxyflavone (DHF), a TrkB agonist, has beneficial effects on neuronal excitotoxicity, stroke, and Parkinson disease in animal models by enhancing axon regeneration, muscle reinnervation and neuromuscular transmission. The effect of DHF on AD neuropathology remains not well defined. In this study we examined whether DHF affects APP processing and cognitive functions in vitro and in vivo. We found that DHF had no significant effect on amyloid β precursor protein (APP), BACE1 and amyloid β protein (Aβ). DHF had little effect on APP processing in cell cultures. DHF treatment did not reduce the deposition of Aβ to form neuritic plaques in the brain of AD model mice APP23/PS45. Furthermore, DHF did not alleviate learning and memory impairments in the AD model mice. Our study suggest that further extensive and careful studies are warranted for considering DHF as a new therapeutic agent for reducing amyloid pathology and alleviating cognitive deficits for AD treatment.
Keywords: Aβ, Alzheimer’s disease, 7, 8-dihydroxyflavone, memory deficits.
Current Alzheimer Research
Title:No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Volume: 12 Issue: 1
Author(s): Weitao Zhou, Xiaoyong Li, Daochao Huang, Weihui Zhou, Tingyu Li and Weihong Song
Affiliation:
Keywords: Aβ, Alzheimer’s disease, 7, 8-dihydroxyflavone, memory deficits.
Abstract: It is reported that 7,8-dihydroxyflavone (DHF), a TrkB agonist, has beneficial effects on neuronal excitotoxicity, stroke, and Parkinson disease in animal models by enhancing axon regeneration, muscle reinnervation and neuromuscular transmission. The effect of DHF on AD neuropathology remains not well defined. In this study we examined whether DHF affects APP processing and cognitive functions in vitro and in vivo. We found that DHF had no significant effect on amyloid β precursor protein (APP), BACE1 and amyloid β protein (Aβ). DHF had little effect on APP processing in cell cultures. DHF treatment did not reduce the deposition of Aβ to form neuritic plaques in the brain of AD model mice APP23/PS45. Furthermore, DHF did not alleviate learning and memory impairments in the AD model mice. Our study suggest that further extensive and careful studies are warranted for considering DHF as a new therapeutic agent for reducing amyloid pathology and alleviating cognitive deficits for AD treatment.
Export Options
About this article
Cite this article as:
Zhou Weitao, Li Xiaoyong, Huang Daochao, Zhou Weihui, Li Tingyu and Song Weihong, No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218124243
DOI https://dx.doi.org/10.2174/1567205012666141218124243 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Dendrimers As Vectors for Genetic Material Delivery to the Nervous System
Current Medicinal Chemistry Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center
Current Pharmaceutical Design Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Catalytic Activity of Certain Antibodies as a Potential Tool for Drug Synthesis and for Directed Prodrug Therapies
Current Medicinal Chemistry